AltaThera Pharmaceuticals, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, chose Dexur’s App Suite to help scale the operations of the company. AltaThera recently received approval from the FDA for new indications of Sotalol IV, to help hospitals manage patients with Afib.
“We chose Dexur because it integrates the myriad of applications such as CRM, Sales Reporting, Medical Information Request (MIRF) and Sunshine Reporting into a single platform that our sales, commercial and other operations can utilize to scale” said Jodi Devlin, AltaThera's CEO
Altathera’s use of Dexur Apps include:
Dexur not only brings the core applications but also the implementation services to customize it to fit the precise needs of Altathera. Unlike, other technology platforms where the implementation services are disconnected underlying technology. This helps Altathera manage costs while scaling the operations of the operations effectively.
About Dexur: Dexur provides technology and data solutions to Life Sciences, Hospitals, and healthcare organizations. Dexur's Life Sciences App suite provides a comprehensive set of applications to help Biopharma, Medical Device, and Life Sciences companies scale effectively.
“Dexur’s App Suite and implementation services is a key strategic partner to help scale ClearFlow. The breadth and depth of Dexur’s offering across data, sales analytics, and marketing automation has made Dexur a critical element in articulating ClearFlow’s value to healthcare providers” said Paul Molloy, CEO of ClearFlow.
ClearFlow’s first commercial solution, the PleuraFlow® ACT® System, improves outcomes for cardiac surgery patients by preventing the most harmful postoperative complications associated with retained blood syndrome (RBS). The System seamlessly integrates into clinical workflow.
“Dexur’s hospital-specific disease burden data combined with personalized microsites elevates our marketing automation to a new level. The program represents a breakthrough in enabling personalized communication at scale, unique in the medical device community” said Stephen Bumb, Vice President Global Marketing at ClearFlow.
ClearFlow’s use of Dexur App suite includes:
“Dexur empowers our representatives by delivering the most relevant data with key machine-generated talking points. This enables our reps to have meaningful conversations about RBS and its impact on cardiac surgery outcomes. We are better equipped to help our customers. Best of all, the solution is easy to navigate and is at the team’s fingertips when they are engaged with customers.” said Michael Elniski, Vice President Global Sales at ClearFlow.
Heron Therapeutics, Inc., a commercial-stage biotechnology company utilizes Dexur’s App suite to increase velocity in commercial operations.
Heron’s use of Dexur’s App suite to increase speed and efficiency in operations include:
“The breadth of Dexur’s App Suite plus the quick customization, implementation and support services have been critical in increasing the velocity of Heron’s commercial operations and supporting our front line reps and commercial operations teams.” said Kourosh Mobini, Sr. Director, Commercial Operations at Heron Therapeutics.